Abstract
TDD with programmable intrathecal drug delivery systems (IDDS) has been approved for malignant and chronic nonmalignant pain treatment since 1991 and severe spasticity since 1992. Identification of rare product performance events within IDDS becomes possible with expanded clinical use, necessitating product modifications to mitigate patient risk. Presented here is real-world evaluation of product performance updated with the most recent data following release of an enhanced IDDS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
